Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics Group, Inc. (TMDX) reported a 26% increase in net revenue for Q4 2020, totaling $7.6 million, driven by a recovery in U.S. OCS Lung procedure volumes. For the full year, revenue rose by 9% to $25.6 million, with a gross margin of 65%. Operating expenses decreased to $43 million due to COVID-19 related reductions. The net loss narrowed to $6.3 million in Q4 and $28.7 million for the year. The company also expanded its National OCS Program and launched several clinical initiatives. A conference call is scheduled for March 2, 2021.
TransMedics Group, Inc. (Nasdaq: TMDX) announced the scheduling of a crucial FDA Advisory Panel meeting on April 6, 2021. This meeting will evaluate the company's premarket approval application for the OCS Heart System, a technology aimed at improving organ transplant procedures. CEO Waleed Hassanein expressed optimism about achieving a positive outcome from the FDA's review process. The company is recognized for its innovations in organ preservation and viability assessment, which seek to enhance the availability and quality of donor organs for critical transplant surgeries.
TransMedics Group (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Cowen 41st Annual Healthcare Conference on March 3, 2021, at 3:20 p.m. EST. The virtual presentation aims to showcase their advancements in organ preservation and assessment, addressing the critical need for improved organ availability for transplantation. A live and archived webcast will be accessible via the TransMedics Investors website. Founded in Andover, Mass., TransMedics focuses on enhancing the viability of donor organs for patients with end-stage heart, lung, and liver failure.
TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2020 financial results on March 2, 2021, after market close. A conference call will follow at 4:30 p.m. ET. The company specializes in organ transplant therapy and aims to improve organ quality and viability assessment. Investors can access the conference by calling (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 3751905. A webcast will be available on their Investor website.
TransMedics Group (Nasdaq: TMDX) announced its management will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2020, at 5:20 p.m. EST. The company specializes in transforming organ transplant therapy through portable extracorporeal warm perfusion technology.
The presentation will be accessible live and in archive via the Investors section of their website.
TransMedics Group announced the appointment of Merilee Raines to its Board of Directors and the Audit Committee, effective January 1, 2021. She will serve as Chair of the Audit Committee starting June 1, 2021. With over 30 years of executive experience, including a significant tenure as CFO at IDEXX Laboratories, Raines is expected to contribute valuable insights as TransMedics aims to enhance its position in the organ transplantation market. CEO Waleed Hassanein expressed confidence in her role for the company's future growth.
TransMedics Group, Inc. (TMDX) reported third-quarter 2020 net revenue of $7.1 million, a 2% decrease from Q3 2019. The decline was primarily due to the ongoing effects of the COVID-19 pandemic. Gross margin improved to 71% from 59% year-over-year, while operating expenses decreased to $9.6 million from $11.5 million. The net loss for the quarter was $5.1 million, a reduction from $8.3 million in the same period last year. Cash reserves stood at $132.7 million as of September 30, 2020.
TransMedics Group, Inc. (NASDAQ: TMDX) announced its participation in two virtual investor conferences. The management team will attend the Oppenheimer Fall MedTech Summit on November 12, 2020, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. These events will consist of 1x1 meetings only, with no webcasts available. TransMedics is a leader in portable extracorporeal warm perfusion for organ transplantation, focusing on enhancing organ quality and viability for patients with end-stage organ failure.
TransMedics Group, Inc. (TMDX) will release its third-quarter financial results on November 4, 2020, after market close. Following this, a conference call will be held at 4:30 p.m. ET. Investors can access the call by dialing (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 1716957. TransMedics is a leader in organ transplant technologies, focusing on enhancing organ quality and increasing the utilization of donor organs for patients with end-stage organ failure.
TransMedics Group announced that the FDA has postponed the Advisory Committee meeting originally set for October 7, 2020, to review its OCS Heart premarket approval application. This delay allows the FDA to evaluate additional data from the OCS Heart EXPAND trial and its Continued Access Protocol. Despite the setback, TransMedics remains confident in the trial results supporting the OCS Heart’s approval to aid heart transplant patients in the U.S.